About Intercept Pharmaceuticals (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000
Debt
Debt-to-Equity Ratio21.71%
Current Ratio4.31%
Quick Ratio4.31%
Price-To-Earnings
Trailing P/E Ratio-4.91
Forward P/E Ratio-5.52
P/E GrowthN/A
Sales & Book Value
Annual Sales$130.96 million
Price / Sales15.56
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book106.51
Profitability
EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-275.18%
Return on Equity-267.95%
Return on Assets-61.90%
Miscellaneous
Employees507
Outstanding Shares29,430,000
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its quarterly earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the consensus estimate of ($3.39) by $1.04. The biopharmaceutical company had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The business's revenue for the quarter was up 173.1% on a year-over-year basis. During the same period last year, the company posted ($4.84) earnings per share. View Intercept Pharmaceuticals' Earnings History.
When is Intercept Pharmaceuticals' next earnings date?
What price target have analysts set for ICPT?
21 brokers have issued 1 year price targets for Intercept Pharmaceuticals' shares. Their predictions range from $50.00 to $256.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $128.5263 in the next twelve months. View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
- 2. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
- 3. Cantor Fitzgerald analysts commented, "Emerging Safety Risks, but PBC Remains Intact. This morning, Intercept reported results demonstrating 3Q17 revenue growth to $36.8 million (excl. $4.1 million one-time increase in deferred revenue) from $31 million in 2Q17. While the FDA warning letter at the end of the quarter potentially shifts the risk-benefit profile of Ocaliva, an analysis of drug scripts provided by Intercept indicates that the sharp drop in scripts around the time of the news has since abated. Net ex-U.S 3Q17 sales increased to $4.7 million from $2.5 million in 2Q17 during the quarter, largely contributed from Germany and France. No formal guidance for the full-year was given, but management noted that they expect sequential quarterly growth for the balance of 2017. While we do not see a negative impact to our long-run commercialization in PBC, we believe the safety events reaffirm the uncertainty for Ocaliva’s use in NASH (where dosing is higher)." (11/1/2017)
- 4. Wells Fargo analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
- 5. Cowen Inc analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), Tesaro (TSRO), Clovis Oncology (CLVS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Ironwood Pharmaceuticals (IRWD), Evotec A.G. (EVTCY) and Puma Biotechnology (PBYI).
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Paolo Fundaro, Independent Chairman of the Board (Age 43)
- Mark Pruzanski M.D., President, Chief Executive Officer, Director (Age 49)
- Sandip S. Kapadia, Chief Financial Officer, Treasurer (Age 47)
- Lisa Bright, President, International (Age 49)
- Jerome Benedict Durso, Chief Operating Officer (Age 49)
- David A Ford, Chief Human Resource Officer
- Richard Kim, Senior Vice President, Commercial U.S. (Age 48)
- David M. Shapiro M.D., Chief Medical Officer (Age 62)
- Srinivas Akkaraju M.D. Ph.D., Independent Director (Age 49)
- Luca Benatti Ph.D., Independent Director (Age 56)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
News headlines about ICPT stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a news sentiment score of 0.07 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 45.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include GENEXTRA S.P.A. (23.30%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $69.23.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $2.17 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $128.5263, suggesting that the stock has a possible upside of 85.65%. The high price target for ICPT is $256.00 and the low price target for ICPT is $50.00. There are currently 3 sell ratings, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.33 | 2.33 | 2.36 | 2.24 |
| Ratings Breakdown: | 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
10 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $128.5263 | $128.3684 | $140.45 | $153.85 |
| Price Target Upside: | 85.65% upside | 106.11% upside | 150.67% upside | 126.95% upside |
Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History
Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Intercept Pharmaceuticals (NASDAQ:ICPT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 64.31%
Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Francesco Micheli | Major Shareholder | Buy | 390,625 | $64.00 | $25,000,000.00 | |  |
| 4/9/2018 | Keith Michael Gottesdiener | Director | Buy | 1,171 | $64.00 | $74,944.00 | 5,001 | |
| 4/9/2018 | Mark Pruzanski | CEO | Buy | 7,812 | $64.00 | $499,968.00 | 11,642 | |
| 10/2/2017 | David Shapiro | CMO | Sell | 349 | $58.90 | $20,556.10 | | |
| 10/2/2017 | Mark Pruzanski | CEO | Sell | 1,532 | $58.87 | $90,188.84 | | |
| 10/2/2017 | Rachel Mcminn | Insider | Sell | 283 | $58.89 | $16,665.87 | | |
| 10/2/2017 | Richard J Kim | SVP | Sell | 48 | $58.10 | $2,788.80 | | |
| 10/2/2017 | Sandip Kapadia | CFO | Sell | 354 | $58.83 | $20,825.82 | | |
| 9/1/2017 | David Shapiro | CMO | Sell | 1,250 | $117.43 | $146,787.50 | 45,812 | |
| 8/25/2017 | Lisa Bright | Insider | Sell | 253 | $111.31 | $28,161.43 | 23,324 | |
| 8/2/2017 | Lisa Bright | Insider | Sell | 142 | $110.29 | $15,661.18 | 23,477 | |
| 8/1/2017 | David Shapiro | CMO | Sell | 1,118 | $119.00 | $133,042.00 | 45,680 | |
| 7/31/2017 | Daniel G Welch | Director | Sell | 602 | $123.93 | $74,605.86 | 3,108 | |
| 7/31/2017 | Rachel Mcminn | Insider | Sell | 130 | $123.12 | $16,005.60 | 17,158 | |
| 7/20/2017 | Daniel G Welch | Director | Sell | 217 | $126.76 | $27,506.92 | 3,710 | |
| 7/14/2017 | Richard J Kim | SVP | Sell | 89 | $128.64 | $11,448.96 | 11,253 | |
| 7/11/2017 | David Shapiro | CMO | Sell | 553 | $124.01 | $68,577.53 | 44,562 | |
| 7/3/2017 | David Shapiro | CMO | Sell | 350 | $121.24 | $42,434.00 | 45,215 | |
| 7/3/2017 | Lisa Bright | Insider | Sell | 394 | $121.33 | $47,804.02 | 23,619 | |
| 7/3/2017 | Mark Pruzanski | CEO | Sell | 1,434 | $121.78 | $174,632.52 | 570,284 | |
| 7/3/2017 | Richard J Kim | SVP | Sell | 50 | $121.69 | $6,084.50 | 11,342 | |
| 7/3/2017 | Sandip Kapadia | CFO | Sell | 1,431 | $121.59 | $173,995.29 | 20,569 | |
| 6/26/2017 | Mark Pruzanski | CEO | Sell | 40,000 | $130.80 | $5,232,000.00 | 611,718 | |
| 6/1/2017 | Lisa Bright | Insider | Sell | 698 | $110.73 | $77,289.54 | 24,711 | |
| 5/25/2017 | Lisa Bright | Insider | Sell | 254 | $117.52 | $29,850.08 | 23,246 | |
| 5/16/2017 | Lisa Bright | Insider | Sell | 113 | $119.74 | $13,530.62 | 23,613 | |
| 5/2/2017 | Lisa Bright | Insider | Sell | 426 | $114.00 | $48,564.00 | 23,804 | |
| 5/1/2017 | David Shapiro | CMO | Sell | 1,117 | $112.18 | $125,305.06 | 46,582 | |
| 5/1/2017 | Rachel Mcminn | Insider | Sell | 114 | $113.12 | $12,895.68 | 17,545 | |
| 4/10/2017 | David Shapiro | CMO | Sell | 558 | $108.51 | $60,548.58 | 45,465 | |
| 4/3/2017 | David Shapiro | CMO | Sell | 346 | $115.00 | $39,790.00 | 46,023 | |
| 4/3/2017 | Lisa Bright | Insider | Sell | 389 | $115.00 | $44,735.00 | 22,925 | |
| 4/3/2017 | Mark Pruzanski | CEO | Sell | 1 | $115.00 | $115.00 | 571,718 | |
| 2/27/2017 | Lisa Bright | Insider | Sell | 254 | $119.48 | $30,347.92 | 21,695 | |
| 1/31/2017 | Lisa Bright | Insider | Sell | 134 | $108.96 | $14,600.64 | 17,383 | |
| 1/9/2017 | David Shapiro | CMO | Sell | 1,565 | $106.01 | $165,905.65 | 40,369 | |
| 1/3/2017 | David Shapiro | CMO | Sell | 988 | $103.92 | $102,672.96 | 41,934 | |
| 1/3/2017 | Mark Pruzanski | CEO | Sell | 2,802 | $103.92 | $291,183.84 | 552,705 | |
| 1/3/2017 | Rachel Mcminn | Insider | Sell | 816 | $103.92 | $84,798.72 | 12,916 | |
| 12/2/2016 | David Shapiro | CMO | Sell | 1,350 | $99.75 | $134,662.50 | 42,922 | |
| 11/25/2016 | Lisa Bright | Insider | Sell | 249 | $113.60 | $28,286.40 | 18,209 | |
| 10/31/2016 | Rachel Mcminn | Insider | Sell | 129 | $123.82 | $15,972.78 | 13,732 | |
| 10/10/2016 | David Shapiro | CMO | Sell | 411 | $153.34 | $63,022.74 | 44,272 | |
| 10/3/2016 | Barbara Gayle Duncan | CAO | Sell | 147 | $163.20 | $23,990.40 | 30,661 | |
| 10/3/2016 | David Shapiro | CMO | Sell | 1,513 | $163.08 | $246,740.04 | 46,196 | |
| 10/3/2016 | Lisa Bright | Insider | Sell | 155 | $163.20 | $25,296.00 | 18,305 | |
| 10/3/2016 | Mark Pruzanski | CEO | Sell | 705 | $163.20 | $115,056.00 | 552,020 | |
| 9/26/2016 | David Shapiro | CMO | Sell | 3,545 | $165.08 | $585,208.60 | 45,732 | |
| 9/20/2016 | Mark Pruzanski | CEO | Sell | 35,000 | $165.00 | $5,775,000.00 | 579,314 | |
| 8/25/2016 | Lisa Bright | Insider | Sell | 246 | $159.00 | $39,114.00 | 18,460 | |
| 8/1/2016 | Rachel Mcminn | Insider | Sell | 125 | $176.57 | $22,071.25 | 13,861 | |
| 7/5/2016 | Barbara Gayle Duncan | CAO | Sell | 146 | $145.11 | $21,186.06 | | |
| 7/5/2016 | David Shapiro | CMO | Sell | 163 | $145.11 | $23,652.93 | | |
| 7/5/2016 | Lisa Bright | Insider | Sell | 155 | $145.11 | $22,492.05 | | |
| 7/5/2016 | Mark Pruzanski | CEO | Sell | 714 | $145.11 | $103,608.54 | | |
| 5/25/2016 | Lisa Bright | Insider | Sell | 251 | $137.50 | $34,512.50 | 18,855 | |
| 5/2/2016 | Rachel Mcminn | Insider | Sell | 130 | $147.49 | $19,173.70 | 14,087 | |
| 4/4/2016 | Barbara Gayle Duncan | CFO | Sell | 144 | $130.76 | $18,829.44 | 30,948 | |
| 4/4/2016 | David Shapiro | CMO | Sell | 165 | $130.76 | $21,575.40 | 48,546 | |
| 4/4/2016 | Lisa Bright | Insider | Sell | 153 | $130.76 | $20,006.28 | 19,106 | |
| 4/4/2016 | Mark Pruzanski | CEO | Sell | 708 | $130.76 | $92,578.08 | 548,248 | |
| 2/25/2016 | Lisa Bright | Insider | Sell | 241 | $115.22 | $27,768.02 | 19,259 | |
| 2/1/2016 | Rachel Mcminn | Insider | Sell | 128 | $103.56 | $13,255.68 | 7,621 | |
| 1/13/2016 | Lisa Bright | insider | Sell | 728 | $125.52 | $91,378.56 | 11,700 | |
| 1/4/2016 | Barbara Gayle Duncan | CFO | Sell | 468 | $145.90 | $68,281.20 | 24,892 | |
| 1/4/2016 | David Shapiro | CMO | Sell | 533 | $145.90 | $77,764.70 | 40,911 | |
| 1/4/2016 | Mark Pruzanski | CEO | Sell | 2,126 | $145.90 | $310,183.40 | 529,556 | |
| 1/4/2016 | Rachel Mcminn | Insider | Sell | 469 | $145.90 | $68,427.10 | 7,749 | |
| 11/25/2015 | Lisa Bright | Insider | Sell | 1,150 | $182.96 | $210,404.00 | 12,428 | |
| 11/16/2015 | David Shapiro | CMO | Sell | 4,264 | $178.53 | $761,251.92 | 28,395 | |
| 11/10/2015 | David Shapiro | CMO | Sell | 3,500 | $204.15 | $714,525.00 | 29,159 | |
| 11/10/2015 | Klaus R. Dr Veitinger | Director | Sell | 1,000 | $198.25 | $198,250.00 | 2,166 | |
| 11/2/2015 | Rachel Mcminn | Insider | Sell | 125 | $160.24 | $20,030.00 | 8,218 | |
| 10/2/2015 | Barbara Gayle Duncan | CFO | Sell | 1,054 | $163.17 | $171,981.18 | 24,062 | |
| 10/2/2015 | David Shapiro | CMO | Sell | 1,140 | $160.12 | $182,536.80 | 29,159 | |
| 9/21/2015 | Nicole Williams | Director | Sell | 973 | $194.82 | $189,559.86 | 962 | |
| 9/15/2015 | David Shapiro | CMO | Sell | 3,500 | $191.28 | $669,480.00 | 23,527 | |
| 8/17/2015 | David Shapiro | CMO | Sell | 4,272 | $209.37 | $894,428.64 | | |
| 7/20/2015 | Nicole Williams | Director | Sell | 973 | $279.01 | $271,476.73 | | |
| 7/10/2015 | Mark Pruzanski | CEO | Sell | 12,500 | $250.00 | $3,125,000.00 | | |
| 7/6/2015 | Luciano Adorini | Insider | Sell | 4,067 | $579.93 | $2,358,575.31 | | |
| 7/1/2015 | Barbara Gayle Duncan | CFO | Sell | 1,000 | $242.10 | $242,100.00 | | |
| 7/1/2015 | David Shapiro | CMO | Sell | 3,781 | $238.66 | $902,373.46 | | |
| 6/22/2015 | Nicole Williams | Director | Sell | 974 | $265.14 | $258,246.36 | | |
| 6/15/2015 | David Shapiro | CMO | Sell | 3,500 | $241.58 | $845,530.00 | | |
| 6/8/2015 | Luciano Adorini | Insider | Sell | 4,000 | $248.40 | $993,600.00 | | |
| 5/11/2015 | Klaus R Dr Veitinger | Director | Sell | 391 | $279.07 | $109,116.37 | | |
| 5/6/2015 | Luciano Adorini | Insider | Sell | 4,000 | $259.97 | $1,039,880.00 | | |
| 4/20/2015 | Nicole Williams | Director | Sell | 974 | $278.50 | $271,259.00 | | |
| 4/6/2015 | Luciano Adorini | Insider | Sell | 4,000 | $269.64 | $1,078,560.00 | | |
| 4/2/2015 | David Shapiro | CMO | Sell | 3,459 | $275.25 | $952,089.75 | | |
| 3/26/2015 | Orbimed Advisors Llc | Director | Sell | 157,200 | $286.75 | $45,077,100.00 | | |
| 3/25/2015 | Orbimed Advisors Llc | Director | Sell | 207,800 | $274.41 | $57,022,398.00 | | |
| 3/24/2015 | Jonathan Silverstein | Director | Sell | 45,600 | $272.00 | $12,403,200.00 | | |
| 3/23/2015 | Jonathan Silverstein | Director | Sell | 159,400 | $275.18 | $43,863,692.00 | | |
| 3/16/2015 | David Shapiro | CMO | Sell | 3,500 | $286.90 | $1,004,150.00 | | |
| 1/12/2015 | Klaus R Dr Veitinger | Director | Sell | 233 | $150.01 | $34,952.33 | | |
| 1/5/2015 | Barbara Gayle Duncan | CFO | Sell | 141 | $176.49 | $24,885.09 | | |
| 1/5/2015 | Daniel Paul Regan | Insider | Sell | 146 | $176.49 | $25,767.54 | | |
| 1/5/2015 | David Shapiro | CMO | Sell | 664 | $172.63 | $114,626.32 | | |
| 1/5/2015 | Mark Pruzanski | CEO | Sell | 461 | $176.49 | $81,361.89 | | |
| 1/2/2015 | Barbara Gayle Duncan | CFO | Sell | 1,000 | $156.40 | $156,400.00 | | |
| 11/17/2014 | David Shapiro | CMO | Sell | 4,790 | $158.82 | $760,747.80 | | |
| 11/12/2014 | Srinivas Akkaraju | Director | Buy | 2,000 | $167.19 | $334,380.00 | | |
| 11/10/2014 | Klaus R Dr Veitinger | Director | Sell | 233 | $175.95 | $40,996.35 | | |
| 11/3/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $259.41 | $2,594,100.00 | | |
| 10/10/2014 | Klaus R Dr Veitinger | Director | Sell | 391 | $223.65 | $87,447.15 | | |
| 10/2/2014 | David Shapiro | CMO | Sell | 5,020 | $231.63 | $1,162,782.60 | | |
| 10/1/2014 | Barbara Gayle Duncan | CFO | Sell | 1,000 | $233.12 | $233,120.00 | | |
| 10/1/2014 | David Shapiro | CMO | Sell | 4,188 | $231.17 | $968,139.96 | | |
| 10/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $228.82 | $2,288,200.00 | | |
| 9/15/2014 | David Shapiro | CMO | Sell | 4,000 | $281.19 | $1,124,760.00 | | |
| 9/10/2014 | Klaus R Dr Veitinger | Director | Sell | 391 | $280.50 | $109,675.50 | | |
| 9/2/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $286.49 | $2,864,900.00 | | |
| 8/27/2014 | David Shapiro | CMO | Sell | 10,000 | $293.93 | $2,939,300.00 | | |
| 8/26/2014 | Orbimed Advisors Llc | Director | Sell | 111,258 | $298.06 | $33,161,559.48 | | |
| 8/25/2014 | Jonathan Silverstein | Director | Sell | 50,000 | $295.59 | $14,779,500.00 | | |
| 8/15/2014 | David Shapiro | CMO | Sell | 4,774 | $291.49 | $1,391,573.26 | | |
| 8/12/2014 | Daniel Paul Regan | Insider | Sell | 8,124 | $325.70 | $2,645,986.80 | | |
| 8/12/2014 | Klaus R Dr Veitinger | Director | Sell | 316 | $345.62 | $109,215.92 | | |
| 8/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $226.72 | $2,267,200.00 | | |
| 7/10/2014 | Klaus R Dr Veitinger | Director | Sell | 391 | $219.15 | $85,687.65 | | |
| 7/7/2014 | Lorenzo Tallarigo | Director | Sell | 2,000 | $243.06 | $486,120.00 | | |
| 7/2/2014 | David Shapiro | CMO | Sell | 5,036 | $244.73 | $1,232,460.28 | | |
| 7/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $250.61 | $2,506,100.00 | | |
| 6/16/2014 | David Shapiro | CMO | Sell | 4,000 | $278.15 | $1,112,600.00 | | |
| 6/2/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $230.60 | $2,306,000.00 | | |
| 5/9/2014 | Lorenzo Tallarigo | Director | Sell | 2,007 | $254.68 | $511,142.76 | | |
| 5/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $263.17 | $2,631,700.00 | 470,174 | |
| 4/16/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $242.22 | $2,422,200.00 | 470,174 | |
| 4/14/2014 | Barbara Gayle Duncan | CFO | Sell | 1,154 | $279.00 | $321,966.00 | 13,510 | |
| 4/10/2014 | Lorenzo Tallarigo | Director | Sell | 349,318 | $317.71 | $110,981,821.78 | 1,640 | |
| 4/9/2014 | Orbimed Advisors Llc | Director | Sell | 81,305 | $320.00 | $26,017,600.00 | | |
| 4/7/2014 | Luciano Adorini | Insider | Sell | 2,000 | $283.90 | $567,800.00 | 7,041 | |
| 4/2/2014 | David Shapiro | CMO | Sell | 5,393 | $331.83 | $1,789,559.19 | 13,679 | |
| 3/17/2014 | David Shapiro | CMO | Sell | 4,456 | $437.49 | $1,949,455.44 | 13,124 | |
| 2/14/2014 | Paolo Fundaro | Director | Sell | 7,246 | $375.26 | $2,719,133.96 | 1,655 | |
| 1/16/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $273.68 | $2,736,800.00 | 430,298 | |
| 1/16/2014 | Srinivas Akkaraju | Director | Sell | 3,250 | $267.94 | $870,805.00 | 1,943 | |
| 1/8/2014 | David Shapiro | CMO | Sell | 4,928 | $71.85 | $354,076.80 | 8,663 | |
| 1/7/2014 | Lorenzo Tallarigo | Director | Sell | 1,839 | $67.41 | $123,966.99 | 1,640 | |
| 1/7/2014 | Luciano Adorini | Insider | Sell | 1,634 | $67.41 | $110,147.94 | 6,392 | |
| 12/16/2013 | David Shapiro | CMO | Sell | 5,016 | $62.11 | $311,543.76 | 3,000 | |
| 10/21/2013 | Francesco Micheli | Major Shareholder | Sell | 124,912 | $62.50 | $7,807,000.00 | | |
| 10/21/2013 | Jonathan Silverstein | Director | Sell | 40,088 | $62.50 | $2,505,500.00 | | |
| 10/21/2013 | Luciano Adorini | Insider | Sell | 2,000 | $55.51 | $111,020.00 | | |
| 10/15/2013 | Francesco Micheli | Major Shareholder | Sell | 1,123,415 | $62.50 | $70,213,437.50 | | |
| 10/15/2013 | Orbimed Advisors Llc | Director | Sell | 376,585 | $62.50 | $23,536,562.50 | | |
| 10/2/2013 | David Shapiro | CMO | Sell | 4,392 | $72.80 | $319,737.60 | | |
| 9/20/2013 | Luciano Adorini | Insider | Sell | 2,000 | $61.07 | $122,140.00 | 5,094 | |
| 9/17/2013 | Mark Pruzanski | CEO | Sell | 25,000 | $52.00 | $1,300,000.00 | 402,032 | |
| 9/13/2013 | Mark Pruzanski | CEO | Sell | 12,500 | $49.02 | $612,750.00 | 402,032 | |
| 8/20/2013 | Luciano Adorini | Insider | Sell | 2,000 | $44.18 | $88,360.00 | 5,094 | |
| 8/16/2013 | David Shapiro | CMO | Sell | 5,016 | $49.20 | $246,787.20 | 4,266 | |
| 8/15/2013 | David Shapiro | CMO | Sell | 4,754 | $45.04 | $214,120.16 | 2,532 | |
| 8/12/2013 | Mark Pruzanski | CEO | Sell | 12,500 | $45.98 | $574,750.00 | 402,032 | |
| 8/12/2013 | Paolo Fundaro | Director | Sell | 4,759 | $46.13 | $219,532.67 | 1,330 | |
| 7/22/2013 | Luciano Adorini | Insider | Sell | 2,000 | $49.44 | $98,880.00 | | |
| 7/15/2013 | Mark Pruzanski | CEO | Sell | 25,000 | $50.05 | $1,251,250.00 | | |
| 7/9/2013 | Mark Pruzanski | CEO | Sell | 37,500 | $46.36 | $1,738,500.00 | | |
| 7/8/2013 | Barbara Gayle Duncan | CFO | Sell | 25,000 | $45.39 | $1,134,750.00 | | |
| 7/2/2013 | David Shapiro | CMO | Sell | 4,369 | $43.63 | $190,619.47 | | |
| 6/26/2013 | Mark Pruzanski | CEO | Sell | 12,500 | $40.06 | $500,750.00 | | |
| 6/20/2013 | Luciano Adorini | Insider | Sell | 2,000 | $37.07 | $74,140.00 | | |
| 6/20/2013 | Mark Pruzanski | CEO | Sell | 25,000 | $38.25 | $956,250.00 | | |
| 6/19/2013 | Barbara Gayle Duncan | CFO | Sell | 50,575 | $34.50 | $1,744,837.50 | | |
| 6/17/2013 | David Shapiro | CMO | Sell | 5,016 | $32.72 | $164,123.52 | | |
| 5/28/2013 | Barbara Gayle Duncan | CFO | Sell | 6,225 | $34.50 | $214,762.50 | | |
| 5/20/2013 | Barbara Gayle Duncan | CFO | Sell | 28,200 | $34.50 | $972,900.00 | | |
| 5/16/2013 | David Shapiro | CMO | Sell | 5,016 | $31.31 | $157,050.96 | | |
| 4/9/2013 | David Shapiro | CMO | Sell | 3,750 | $34.41 | $129,037.50 | | |
| 10/16/2012 | Jonathan Silverstein | Director | Buy | 333,334 | $15.00 | $5,000,010.00 | | |
(Data available from 1/1/2013 forward)
Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Research Analysts Set Expectations for Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - April 19 at 7:08 AM |
| BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Buy"
www.americanbankingnews.com - April 18 at 10:06 AM |
| Jefferies Group Weighs in on Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - April 18 at 7:54 AM |
| Intercept Pharmaceuticals (ICPT) Given New $256.00 Price Target at Wedbush
www.americanbankingnews.com - April 17 at 8:49 AM |
 | Intercept Reports Phase III Sub-Study Liver Biopsy Data
www.zacks.com - April 16 at 5:01 PM |
| Intercept Pharmaceuticals (ICPT) Receives Hold Rating from Laidlaw
www.americanbankingnews.com - April 14 at 2:30 PM |
 | 11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA)
globenewswire.com - April 13 at 8:55 AM |
 | Intercept Pharma's obeticholic acid shows positive effect on fibrosis and cirrhosis in late-stage study; shares up 3% premarket
seekingalpha.com - April 13 at 8:55 AM |
| CymaBay Therapeutics Pushes Itself To The Next Stage Against Rare Liver Disease
seekingalpha.com - April 12 at 9:21 AM |
| Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Quarterly Sales of $38.55 Million
www.americanbankingnews.com - April 10 at 2:56 AM |
| Intercept Pharmaceuticals Inc (ICPT) CEO Acquires $499,968.00 in Stock
www.americanbankingnews.com - April 9 at 10:26 PM |
| Intercept Pharmaceuticals Inc (ICPT) Director Keith Michael Gottesdiener Acquires 1,171 Shares
www.americanbankingnews.com - April 9 at 10:26 PM |
| Intercept Pharmaceuticals Inc (ICPT) Major Shareholder Francesco Micheli Purchases 390,625 Shares
www.americanbankingnews.com - April 9 at 7:16 PM |
 | A Look at Intercept Pharmaceuticals’ Cash Flows
finance.yahoo.com - April 9 at 8:54 AM |
| Royal Bank of Canada Raises Intercept Pharmaceuticals (ICPT) Price Target to $244.00
www.americanbankingnews.com - April 8 at 5:25 PM |
| Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Earnings of -$3.42 Per Share
www.americanbankingnews.com - April 8 at 3:10 PM |
| Intercept Pharmaceuticals (ICPT) Cut to "Market Perform" at JMP Securities
www.americanbankingnews.com - April 7 at 10:28 PM |
| Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
finance.yahoo.com - April 7 at 9:04 AM |
| Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher
www.zacks.com - April 6 at 8:56 AM |
| Today’s Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus Pharmaceuticals
finance.yahoo.com - April 6 at 8:56 AM |
| Analysts’ Ratings for Intercept Pharmaceuticals in April
finance.yahoo.com - April 6 at 8:56 AM |
 | Intercept Pharma (ICPT) Plans $120 Million Public Offering of Common Stock, Concurrent $92 Million Private Placement
www.streetinsider.com - April 5 at 4:59 PM |
| Why Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped Today
finance.yahoo.com - April 5 at 4:59 PM |
| Intercept Pharmaceuticals (ICPT) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM |
| Intercept Pharma prices upsized stock offering at $64; shares up 1% premarket
seekingalpha.com - April 5 at 10:47 AM |
| Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock
finance.yahoo.com - April 5 at 10:47 AM |
| Intercept Pharmaceuticals (ICPT) Upgraded at Laidlaw
www.americanbankingnews.com - April 2 at 11:16 AM |
| Intercept Pharmaceuticals Inc (ICPT) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 31 at 8:11 AM |
| Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 10:49 PM |
| Needham & Company LLC Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - March 28 at 9:16 PM |
| BidaskClub Lowers Intercept Pharmaceuticals (ICPT) to Strong Sell
www.americanbankingnews.com - March 28 at 12:34 AM |
| Intercept Pharmaceuticals (ICPT) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 25 at 5:24 PM |
| Intercept Pharmaceuticals (ICPT) Downgraded by Goldman Sachs
www.americanbankingnews.com - March 25 at 7:44 AM |
| $38.55 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter
www.americanbankingnews.com - March 24 at 4:49 AM |
| Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress™ 2018
finance.yahoo.com - March 23 at 8:47 AM |
| Intercept Pharmaceuticals' (ICPT) "Hold" Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - March 21 at 7:48 PM |
| New Research: Key Drivers of Growth for LTC Properties, NACCO Industries, Viad, Resource Capital, WageWorks, and Intercept Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - March 21 at 9:36 AM |
| Edited Transcript of ICPT earnings conference call or presentation 14-Feb-18 1:30pm GMT
finance.yahoo.com - March 21 at 9:36 AM |
| Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue?
finance.yahoo.com - March 16 at 6:05 PM |
| CORRECTING and REPLACING -- Intercept to Present at Upcoming Conference
finance.yahoo.com - March 13 at 6:57 PM |
| Intercept Pharmaceuticals Inc to Post FY2021 Earnings of $10.38 Per Share, Wedbush Forecasts (ICPT)
www.americanbankingnews.com - March 12 at 9:41 AM |
| Intercept Pharmaceuticals (ICPT) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - March 9 at 8:11 AM |
 | Research finds female analysts are more accurate, make bolder calls - CNBC
www.cnbc.com - March 8 at 6:10 PM |
| $38.46 Million in Sales Expected for Intercept Pharmaceuticals Inc (ICPT) This Quarter
www.americanbankingnews.com - March 7 at 1:59 PM |
| Intercept Pharmaceuticals Inc (ICPT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 6 at 1:39 PM |
| Hudson Bay Capital Management LP Invests $1.75 Million in Intercept Pharmaceuticals Inc (ICPT) Stock
www.americanbankingnews.com - March 2 at 12:49 PM |
| Altrinsic Global Advisors LLC Grows Stake in Intercept Pharmaceuticals Inc (ICPT)
www.americanbankingnews.com - March 2 at 4:16 AM |
| Senvest Management LLC Increases Holdings in Intercept Pharmaceuticals Inc (ICPT)
www.americanbankingnews.com - February 26 at 4:02 PM |
| Spark Investment Management LLC Has $10.58 Million Holdings in Intercept Pharmaceuticals Inc (ICPT)
www.americanbankingnews.com - February 25 at 2:31 PM |
| Intercept Pharmaceuticals (ICPT) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - February 19 at 1:08 PM |
Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement
Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Thursday, April, 19, 2018
Loading chart…
